InspireMD announced the establishment of its global headquarters in Miami, Florida. The new facility will ideally position the Company to support the anticipated U.S. launch and commercialization of the CGuard Prime carotid stent system in the first half of 2025, if approved. Marvin Slosman, Chief Executive Officer of InspireMD, stated, “The establishment of our new headquarters location in the U.S. represents a significant step as we prepare for potential FDA approval of CGuard Prime in the first half of next year. Together with the ongoing build-out of world class commercial and operational teams and supporting infrastructure, our new U.S.-based headquarters will be key to driving long-term growth and serving the U.S. market while creating sustained shareholder value.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NSPR:
- InspireMD announces approval of IDE application for CGUARDIANS II study
- InspireMD Advances with FDA Study Approval and Global Goals
- InspireMD Launches 2024 Plan to Attract Talent with Stock
- InspireMD Advances Stroke Prevention with FDA PMA Submission
- InspireMD submits premarket approval application for CGuard Prime system